title: [A long-term surviving patient with unresectable lung metastasis from colon cancer treated with intravenous administration of activated autologous lymphocytes and low-dose chemotherapy--a case report].
abstract: We herein report a case of long-term surviving patient who was treated with intravenous administration of activated autologous lymphocytes and low-dose chemotherapy. The patient was an 82-year-old female. She underwent radical resection for sigmoid colon cancer in 1998 and right lobectomy of the liver for metastatic liver tumor in 2001. A follow up CT revealed the metastasis to the bilateral lung on November 2003. Then she received a treatment with UFT plus low-dose CPT-11/CDDP and activated autologous lymphocytes. Although the response of the treatment was SD, the serum CEA level decreased to a normal range. The treatment continued with delayed administration for 30 months while CEA and the size of the tumors increased very slowly. After that, her treatment was changed with a single administration of S-1. She obtained a 3.5 year survival with an inhibition of fast tumor growth by chemo-immunotherapy.
authors.affiliation: Dept. of Surgery, Tokyo Women's Medical University Medical Center East.
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Yoshimatsu
authors.forename: Hajime
authors.initials: H
authors.lastname: Yokomizo
authors.forename: Takashi
authors.initials: T
authors.lastname: Fujimoto
authors.forename: Taisuke
authors.initials: T
authors.lastname: Otani
authors.forename: Gakuji
authors.initials: G
authors.lastname: Osawa
authors.forename: Arihiro
authors.initials: A
authors.lastname: Umehara
authors.forename: Atsuo
authors.initials: A
authors.lastname: Matsumoto
authors.forename: Kotaro
authors.initials: K
authors.lastname: Kuhara
authors.forename: Takeshi
authors.initials: T
authors.lastname: Shimakawa
authors.forename: Kenji
authors.initials: K
authors.lastname: Ogawa
mesh_terms: D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007167:Immunotherapy; D007275:Injections, Intravenous; D000077146:Irinotecan; D008175:Lung Neoplasms / Q000276:immunology* / Q000473:pathology / Q000556:secondary / Q000628:therapy*; D008213:Lymphocyte Activation; D017710:Lymphocyte Transfusion; D008214:Lymphocytes / Q000276:immunology*; D010094:Oxonic Acid / Q000008:administration & dosage / Q000627:therapeutic use; D012811:Sigmoid Neoplasms / Q000473:pathology* / Q000601:surgery; D005641:Tegafur / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D014182:Transplantation, Autologous; D014498:Uracil / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D014498:Uracil; D010094:Oxonic Acid; D000077146:Irinotecan; D002945:Cisplatin; D002166:Camptothecin